These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24619377)

  • 21. Cabozantinib in ovarian clear cell cancers: UnMET expectations.
    Secord AA; Previs RA; Nixon AB
    Gynecol Oncol; 2018 Jul; 150(1):1-2. PubMed ID: 29935857
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
    Galsky MD; Small AC; Tsao CK; Oh WK
    CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cabozantinib in Thyroid Cancer.
    Fallahi P; Ferrari SM; Di Bari F; Materazzi G; Benvenga S; Miccoli P; Antonelli A
    Recent Pat Anticancer Drug Discov; 2015; 10(3):259-69. PubMed ID: 26152149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
    Abou-Alfa GK; Meyer T; Cheng AL; El-Khoueiry AB; Rimassa L; Ryoo BY; Cicin I; Merle P; Chen Y; Park JW; Blanc JF; Bolondi L; Klümpen HJ; Chan SL; Zagonel V; Pressiani T; Ryu MH; Venook AP; Hessel C; Borgman-Hagey AE; Schwab G; Kelley RK
    N Engl J Med; 2018 Jul; 379(1):54-63. PubMed ID: 29972759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabozantinib Unlocks Efficient
    Chaudagar KK; Landon-Brace N; Solanki A; Hieromnimon HM; Hegermiller E; Li W; Shao Y; Joseph J; Wilkins DJ; Bynoe KM; Li XL; Clohessy JG; Ullas S; Karp JM; Patnaik A
    Mol Cancer Ther; 2021 Feb; 20(2):438-449. PubMed ID: 33277441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
    Wang X; Huang Y; Christie A; Bowden M; Lee GS; Kantoff PW; Sweeney CJ
    Clin Cancer Res; 2015 Dec; 21(24):5578-87. PubMed ID: 26289068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
    Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
    Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.
    Nguyen HM; Ruppender N; Zhang X; Brown LG; Gross TS; Morrissey C; Gulati R; Vessella RL; Schimmoller F; Aftab DT; Corey E
    PLoS One; 2013; 8(10):e78881. PubMed ID: 24205338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma.
    Liao W; Huang J; Hutton D; Zhu G; Wu Q; Wen F; Bai L; Li Q
    Liver Int; 2019 Dec; 39(12):2408-2416. PubMed ID: 31544330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.
    Qiao Y; Feng FY; Wang Y; Cao X; Han S; Wilder-Romans K; Navone NM; Logothetis C; Taichman RS; Keller ET; Palapattu GS; Alva AS; Smith DC; Tomlins SA; Chinnaiyan AM; Morgan TM
    Neoplasia; 2016 Jan; 18(1):1-9. PubMed ID: 26806347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma.
    Deeks ED
    Target Oncol; 2019 Feb; 14(1):107-113. PubMed ID: 30767164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hand-foot skin reaction with primarily dorsal involvement in a patient with metastatic renal cell carcinoma on cabozantinib.
    Goyal A; Jacobsen AA; O'Leary D; Watson A; Luikart S; Gaddis KJ
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
    Martínez Chanzá N; Xie W; Asim Bilen M; Dzimitrowicz H; Burkart J; Geynisman DM; Balakrishnan A; Bowman IA; Jain R; Stadler W; Zakharia Y; Narayan V; Beuselinck B; McKay RR; Tripathi A; Pachynski R; Hahn AW; Hsu J; Shah SA; Lam ET; Rose TL; Mega AE; Vogelzang N; Harrison MR; Mortazavi A; Plimack ER; Vaishampayan U; Hammers H; George S; Haas N; Agarwal N; Pal SK; Srinivas S; Carneiro BA; Heng DYC; Bosse D; Choueiri TK; Harshman LC
    Lancet Oncol; 2019 Apr; 20(4):581-590. PubMed ID: 30827746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
    Heidenreich A; Chowdhury S; Klotz L; Siemens DR; Villers A; Ivanescu C; Holmstrom S; Baron B; Wang F; Lin P; Shore ND
    Eur Urol; 2017 Apr; 71(4):534-542. PubMed ID: 27497762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
    Grüllich C
    Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib.
    Roy S; Narang BK; Rastogi SK; Rawal RK
    Anticancer Agents Med Chem; 2015; 15(1):37-47. PubMed ID: 25181996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.